Novara Mark David 4

What Happened
Mark Novara, EVP & Chief Commercial Officer of Tandem Diabetes Care (TNDM), had 77 restricted stock units (RSUs convert to shares) vest/convert on Feb 17, 2026. Of those 77 shares, 62 were withheld by the company to satisfy tax withholding at $18.95/share (total value withheld ≈ $1,175). The filing indicates no shares were sold on the open market; net shares delivered to Novara were 15 (77 vested − 62 withheld).

Key Details

• Transaction date: 2026-02-17.
• Actions reported: Exercise/conversion of derivative (code M) for 77 RSUs → 77 shares; tax-withholding (code F) of 62 shares at $18.95/share (total ≈ $1,175).
• Net shares received by insider from this vesting: 15 shares.
• Shares owned after transaction: not reported on this Form 4.
• Footnotes: RSUs were awarded May 23, 2024 under the 2023 Long-Term Incentive Plan; each RSU converts to one share (or cash at issuer's discretion). Vesting schedule: 33% on 5/15/2025, remaining shares vest in eight equal quarterly installments. The filing notes the withholding was done by the company to satisfy tax obligations; no market sale occurred.
• Filing timeliness: No late-filing indication appears on this Form 4.

Context

• These transactions reflect routine RSU vesting and employer tax withholding, not an open-market sale or purchase. For derivative/RSU activity, the common pattern is shares are issued on vesting and some withheld to cover taxes (a cashless settlement). This is informational about compensation vesting rather than a directional trade by the insider.